BioMarin Pharmaceutical (NASDAQ: BMRN) reported its third-quarter earnings after market close Monday, and they were good ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

Ultragenyx Pharmaceutical (RARE) shares have seen some movement lately, attracting attention from investors curious about the company’s direction. The stock has delivered a 21% gain over the past ...

A new article published in the Journal of Medical Internet Research challenges the foundational research model that has ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy ...

Fintel reports that on October 28, 2025, Morgan Stanley maintained coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a ...

The Federal Government and the European Union have announced plans to hold a summit on local pharmaceutical production and ...

"The threshold debate in Norway" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...

D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents – manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, ...

"Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks," Texas Attorney General Ken ...

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to ...